Cargando…
E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase mo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792013/ https://www.ncbi.nlm.nih.gov/pubmed/31424118 http://dx.doi.org/10.15252/embj.2018101443 |
_version_ | 1783459065415860224 |
---|---|
author | Burdova, Kamila Yang, Hongbin Faedda, Roberta Hume, Samuel Chauhan, Jagat Ebner, Daniel Kessler, Benedikt M Vendrell, Iolanda Drewry, David H Wells, Carrow I Hatch, Stephanie B Dianov, Grigory L Buffa, Francesca M D'Angiolella, Vincenzo |
author_facet | Burdova, Kamila Yang, Hongbin Faedda, Roberta Hume, Samuel Chauhan, Jagat Ebner, Daniel Kessler, Benedikt M Vendrell, Iolanda Drewry, David H Wells, Carrow I Hatch, Stephanie B Dianov, Grigory L Buffa, Francesca M D'Angiolella, Vincenzo |
author_sort | Burdova, Kamila |
collection | PubMed |
description | Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase module. Although various substrates of cyclin F have been identified, the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging them with more than 180 different kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss. Chk1 inhibition in cells lacking cyclin F leads to DNA replication catastrophe. Replication catastrophe depends on accumulation of the transcription factor E2F1 in cyclin F‐depleted cells. We find that SCF‐cyclin F controls E2F1 ubiquitylation and degradation during the G2/M phase of the cell cycle and upon challenging cells with Chk1 inhibitors. Thus, Cyclin F restricts E2F1 activity during the cell cycle and upon checkpoint inhibition to prevent DNA replication stress. Our findings pave the way for patient selection in the clinical use of checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-6792013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67920132019-10-21 E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition Burdova, Kamila Yang, Hongbin Faedda, Roberta Hume, Samuel Chauhan, Jagat Ebner, Daniel Kessler, Benedikt M Vendrell, Iolanda Drewry, David H Wells, Carrow I Hatch, Stephanie B Dianov, Grigory L Buffa, Francesca M D'Angiolella, Vincenzo EMBO J Articles Cyclins are central engines of cell cycle progression in conjunction with cyclin‐dependent kinases (CDKs). Among the different cyclins controlling cell cycle progression, cyclin F does not partner with a CDK, but instead forms via its F‐box domain an SCF (Skp1‐Cul1‐F‐box)‐type E3 ubiquitin ligase module. Although various substrates of cyclin F have been identified, the vulnerabilities of cells lacking cyclin F are not known. Thus, we assessed viability of cells lacking cyclin F upon challenging them with more than 180 different kinase inhibitors. The screen revealed a striking synthetic lethality between Chk1 inhibition and cyclin F loss. Chk1 inhibition in cells lacking cyclin F leads to DNA replication catastrophe. Replication catastrophe depends on accumulation of the transcription factor E2F1 in cyclin F‐depleted cells. We find that SCF‐cyclin F controls E2F1 ubiquitylation and degradation during the G2/M phase of the cell cycle and upon challenging cells with Chk1 inhibitors. Thus, Cyclin F restricts E2F1 activity during the cell cycle and upon checkpoint inhibition to prevent DNA replication stress. Our findings pave the way for patient selection in the clinical use of checkpoint inhibitors. John Wiley and Sons Inc. 2019-08-19 2019-10-15 /pmc/articles/PMC6792013/ /pubmed/31424118 http://dx.doi.org/10.15252/embj.2018101443 Text en © 2019 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Burdova, Kamila Yang, Hongbin Faedda, Roberta Hume, Samuel Chauhan, Jagat Ebner, Daniel Kessler, Benedikt M Vendrell, Iolanda Drewry, David H Wells, Carrow I Hatch, Stephanie B Dianov, Grigory L Buffa, Francesca M D'Angiolella, Vincenzo E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title | E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title_full | E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title_fullStr | E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title_full_unstemmed | E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title_short | E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition |
title_sort | e2f1 proteolysis via scf‐cyclin f underlies synthetic lethality between cyclin f loss and chk1 inhibition |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792013/ https://www.ncbi.nlm.nih.gov/pubmed/31424118 http://dx.doi.org/10.15252/embj.2018101443 |
work_keys_str_mv | AT burdovakamila e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT yanghongbin e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT faeddaroberta e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT humesamuel e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT chauhanjagat e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT ebnerdaniel e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT kesslerbenediktm e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT vendrelliolanda e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT drewrydavidh e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT wellscarrowi e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT hatchstephanieb e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT dianovgrigoryl e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT buffafrancescam e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition AT dangiolellavincenzo e2f1proteolysisviascfcyclinfunderliessyntheticlethalitybetweencyclinflossandchk1inhibition |